North America is expected to hold
a dominant position in the market, increasing focus of manufacturers on novel
drug development for ALS
North America is expected to hold
a dominant position in the Amyotrophic
Lateral Sclerosis Treatment Market, as major companies present in the
region are focusing on collaborations for product development. For instance, in
January 2018 Sangamo Therapeutics, Inc. and Pfizer Inc. collaborated for the
development of a potential gene therapy using zinc finger protein transcription
factors (ZFP-TFs) for the treatment of ALS. Companies based in emerging
economies of Asia Pacific are focusing on developing novel drugs for treatment
of ALS. For instant major companies such as Mitsubishi Tanabe Pharma
Corporation and Takeda Pharmaceutical Company Ltd are developing drugs for
treatment of ALS.
Amyotrophic lateral sclerosis
(ALS), also known as Lou Gehrig's disease and motor neuron disease (MND), is a
neurodegenerative disease, affecting nerve cells in the brain and spinal cord
that controls voluntary muscles. The disease is progressive in nature, meaning
it gets worse over time.
According to a study published in
Centers for Disease Control and Prevention, in 2016, around 14,713 people were
diagnosed with ALS in the U.S. and prevalence rate of ALS was 4.7 cases per
100,000 people in 2012. The prevalence rate increased to 5.0 cases per 100,000
people and around 15,908 people were diagnosed with ALS in 2013, according to
the same study.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1206
The increasing prevalence of ALS
is in turn, expected to support growth of the amyotrophic lateral sclerosis
(ALS) treatment market in the near future.
Approval of novel innovative
drugs is expected to boost growth in amyotrophic lateral sclerosis treatment
market
In May 2017, The U.S. Food and
Drug Administration (FDA) approved Radicava (edaravone), an innovative drug
used in the treatment of amyotrophic lateral sclerosis (ALS). This was the
first drug to be approved after over 20 years since the last FDA-approved drug
for ALS. The approval of this drug would provide an additional option for
patients suffering from this deadly disease. Increasing incidence of ALS is
expected to increase the adoption rate of this drug, in turn, boosting market
growth. The drug has already been approved in Japan and South Korea in 2015.
Initiatives taken by some
associations to increase awareness about diagnosis and treatment of ALS among
population is also expected to drive market growth during forecast period
(2017-2025). For instance in 2014, the ALS Ice Bucket Challenge, a social
media–centered campaign, received extensive public visibility and created
increased awareness of ALS. In 2015, a group of ALS organizations in the U.S.,
including the ALS Association, Les Turner ALS Foundation, and ALS Therapy
Development Institute, re-introduced the Ice Bucket Challenge to raise further
funds and spread awareness about ALS among population.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/amyotrophic-lateral-sclerosis-treatment-market-1206
Major players are collaborating
with various research institutes and companies for the development of drug for
amyotrophic lateral sclerosis treatment
In December 2017, Mitsubishi
Tanabe Pharma Corporation, Order made Medical Research Corporation and Trans
Chromosomics Inc. have completed strategic collaboration for the development of
antibody drug to treat neurodegenerative diseases such as ALS. Takeda
Pharmaceutical Company Ltd. collaborated with Montreal Neurological Institute
for the discovery of new drugs for ALS in the same month. In 2016, Evotec and
Celgene Corporation have entered into a strategic drug discovery for the
development of new drugs for neurodegenerative diseases such as ALS. In 2013
Janssen Research & Development, Division of Janssen Pharmaceutica NV, and
Johnson & Johnson collaborated, with three prominent Belgian academic
institutions and research centers for the discovery of new treatment drugs for
neurodegenerative diseases such as ALS.
Major players operating in the
global amyotrophic lateral sclerosis treatment market include Mitsubishi Tanabe
Pharma, Takeda Pharmaceutical Company Ltd., Sanofi S.A., and Mylan
Pharmaceuticals Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1206
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment